AstraZeneca is to terminate its antiviral licensing agreement with Biota after the Australian company's BTA9881 failed to meet safety requirements in a Phase Ia clinical trial for respiratory synctial virus (RSV).
AstraZeneca is to terminate its antiviral licensing agreement with Biota after the Australian company's BTA9881 failed to meet safety requirements in a Phase Ia clinical trial for respiratory synctial virus (RSV).
BTA9881 exhibited nearly 100% oral bioavailability in humans and a safety profile in humans comparable with placebo at the doses...
Dr Reddy’s CEO discusses the growth opportunity for semaglutide, including production capacity and ‘crazy’ demand indications, and a potential 20-plus product GLP-1 portfolio. All eyes are also on an upcoming hearing in India pertaining to Novo Nordisk’s semaglutide patent in the country.
Deal Snapshot: The addition of Hengrui's HRS-9821, a China-originated fast-follower of Verona’s Ohtuvayre in chronic obstructive pulmonary disease, should enable GSK’s COPD therapy portfolio to stack up well against increasing competitors in the indication, including biologics and small molecules.
In this week's episode: Sanofi’s Vicebio buy; Sarepta halts US Elevidys shipments; Novartis warning over Europe; US CRL for Genentech’s Columvi; and an interview with Novavax.
